Loading…

A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy

Background  Repeated applications of a corticosteroid can induce epidermal atrophy. This study was performed to investigate whether the adjunctive use of tazarotene gel 0.1% might help to minimize the development of steroid‐induced epidermal atrophy. Methods  Each of 24 healthy volunteers received t...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2001-07, Vol.40 (7), p.468-471
Main Authors: Kaidbey, Kays, Kopper, Scott C., Sefton, John, Gibson, John R.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5244-538283aa71c06cca73c5b29c2783c9d4842121415b7a7149902f0cc20ed932893
cites cdi_FETCH-LOGICAL-c5244-538283aa71c06cca73c5b29c2783c9d4842121415b7a7149902f0cc20ed932893
container_end_page 471
container_issue 7
container_start_page 468
container_title International journal of dermatology
container_volume 40
creator Kaidbey, Kays
Kopper, Scott C.
Sefton, John
Gibson, John R.
description Background  Repeated applications of a corticosteroid can induce epidermal atrophy. This study was performed to investigate whether the adjunctive use of tazarotene gel 0.1% might help to minimize the development of steroid‐induced epidermal atrophy. Methods  Each of 24 healthy volunteers received the following six treatments (applied 6 days per week for 4 weeks), which were randomized to each of six sites on their forearms: no treatment, tazarotene vehicle, tazarotene vehicle + tazarotene gel 0.1%, diflorasone diacetate 0.05% ointment, diflorasone diacetate 0.05% ointment + tazarotene vehicle, or diflorasone diacetate 0.05% ointment + tazarotene gel 0.1%. Results  The mean epidermal thickness was increased by 20% (NS) and 62% (P ≤ 0.0005) after applications of tazarotene vehicle and tazarotene gel 0.1%, respectively. Application of diflorasone diacetate reduced the mean epidermal thickness by 43% (P ≤ 0.0005). Concomitant application of tazarotene gel 0.1% with diflorasone diacetate did not entirely prevent atrophy, but was shown to ameliorate 37% of the epidermal atrophy induced by diflorasone diacetate alone (P ≤ 0.003 compared with steroid monotherapy). Conclusions  Tazarotene gel 0.1% significantly reduces epidermal atrophy induced by diflorasone diacetate 0.05% ointment.
doi_str_mv 10.1046/j.1365-4362.2001.01234.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_222900500</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>86943220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5244-538283aa71c06cca73c5b29c2783c9d4842121415b7a7149902f0cc20ed932893</originalsourceid><addsrcrecordid>eNqNkEtv3CAURlHUqpmk_QsRqpSlHV7GZtFFlDSPKm0WmSpLxABumHqMA1idya8vjkfNtitA95x7Lx8AEKMSI8bP1iWmvCoY5aQkCOESYUJZuT0Ai7nAKXkHFrmCC4EqcQiOYlznJyWYfQCHGPNaIMQXQJ3DwXU-wZhGs4PJQ2OTDRvXW5ieLLRta3WCvoVJvajgk82FX7aDeZNT6Pvs2eCdKVxvRm0NtIMz2VcdVCn44Wn3EbxvVRftp_15DH5efV1e3BR399e3F-d3ha4IY0VFG9JQpWqsEdda1VRXKyI0qRuqhWENIzgvj6tVnRkmBCIt0pogawQljaDH4PPcdwj-ebQxybUfQ59HSkJI_m2FUIaaGdLBxxhsK4fgNirsJEZyilau5ZSgnKKVU7TyNVq5zerJvv-42ljzJu6zzMDpHlBRq64NqtcuvnEM1Q1mJHNfZu6P6-zuvxeQt98up1v2i9l3OfvtP1-F35LXtK7k449r-bjklw_fOZVL-hfqWqEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222900500</pqid></control><display><type>article</type><title>A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Kaidbey, Kays ; Kopper, Scott C. ; Sefton, John ; Gibson, John R.</creator><creatorcontrib>Kaidbey, Kays ; Kopper, Scott C. ; Sefton, John ; Gibson, John R.</creatorcontrib><description>Background  Repeated applications of a corticosteroid can induce epidermal atrophy. This study was performed to investigate whether the adjunctive use of tazarotene gel 0.1% might help to minimize the development of steroid‐induced epidermal atrophy. Methods  Each of 24 healthy volunteers received the following six treatments (applied 6 days per week for 4 weeks), which were randomized to each of six sites on their forearms: no treatment, tazarotene vehicle, tazarotene vehicle + tazarotene gel 0.1%, diflorasone diacetate 0.05% ointment, diflorasone diacetate 0.05% ointment + tazarotene vehicle, or diflorasone diacetate 0.05% ointment + tazarotene gel 0.1%. Results  The mean epidermal thickness was increased by 20% (NS) and 62% (P ≤ 0.0005) after applications of tazarotene vehicle and tazarotene gel 0.1%, respectively. Application of diflorasone diacetate reduced the mean epidermal thickness by 43% (P ≤ 0.0005). Concomitant application of tazarotene gel 0.1% with diflorasone diacetate did not entirely prevent atrophy, but was shown to ameliorate 37% of the epidermal atrophy induced by diflorasone diacetate alone (P ≤ 0.003 compared with steroid monotherapy). Conclusions  Tazarotene gel 0.1% significantly reduces epidermal atrophy induced by diflorasone diacetate 0.05% ointment.</description><identifier>ISSN: 0011-9059</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1046/j.1365-4362.2001.01234.x</identifier><identifier>PMID: 11679006</identifier><identifier>CODEN: IJDEBB</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adrenal Cortex Hormones - pharmacology ; Adult ; Atrophy - chemically induced ; Atrophy - prevention &amp; control ; Betamethasone - analogs &amp; derivatives ; Betamethasone - pharmacology ; Biological and medical sciences ; Biopsy ; Dermatologic Agents - pharmacology ; Dermatologic Agents - therapeutic use ; Double-Blind Method ; Female ; Gels ; Humans ; Male ; Medical sciences ; Middle Aged ; Nicotinic Acids - pharmacology ; Nicotinic Acids - therapeutic use ; Pharmacology. Drug treatments ; Pilot Projects ; Skin - drug effects ; Skin - pathology ; Skin Diseases - chemically induced ; Skin Diseases - pathology ; Skin Diseases - prevention &amp; control ; Skin, nail, hair, dermoskeleton ; Treatment Outcome</subject><ispartof>International journal of dermatology, 2001-07, Vol.40 (7), p.468-471</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Jul 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5244-538283aa71c06cca73c5b29c2783c9d4842121415b7a7149902f0cc20ed932893</citedby><cites>FETCH-LOGICAL-c5244-538283aa71c06cca73c5b29c2783c9d4842121415b7a7149902f0cc20ed932893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14078142$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11679006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaidbey, Kays</creatorcontrib><creatorcontrib>Kopper, Scott C.</creatorcontrib><creatorcontrib>Sefton, John</creatorcontrib><creatorcontrib>Gibson, John R.</creatorcontrib><title>A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Background  Repeated applications of a corticosteroid can induce epidermal atrophy. This study was performed to investigate whether the adjunctive use of tazarotene gel 0.1% might help to minimize the development of steroid‐induced epidermal atrophy. Methods  Each of 24 healthy volunteers received the following six treatments (applied 6 days per week for 4 weeks), which were randomized to each of six sites on their forearms: no treatment, tazarotene vehicle, tazarotene vehicle + tazarotene gel 0.1%, diflorasone diacetate 0.05% ointment, diflorasone diacetate 0.05% ointment + tazarotene vehicle, or diflorasone diacetate 0.05% ointment + tazarotene gel 0.1%. Results  The mean epidermal thickness was increased by 20% (NS) and 62% (P ≤ 0.0005) after applications of tazarotene vehicle and tazarotene gel 0.1%, respectively. Application of diflorasone diacetate reduced the mean epidermal thickness by 43% (P ≤ 0.0005). Concomitant application of tazarotene gel 0.1% with diflorasone diacetate did not entirely prevent atrophy, but was shown to ameliorate 37% of the epidermal atrophy induced by diflorasone diacetate alone (P ≤ 0.003 compared with steroid monotherapy). Conclusions  Tazarotene gel 0.1% significantly reduces epidermal atrophy induced by diflorasone diacetate 0.05% ointment.</description><subject>Adrenal Cortex Hormones - pharmacology</subject><subject>Adult</subject><subject>Atrophy - chemically induced</subject><subject>Atrophy - prevention &amp; control</subject><subject>Betamethasone - analogs &amp; derivatives</subject><subject>Betamethasone - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Dermatologic Agents - pharmacology</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Gels</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nicotinic Acids - pharmacology</subject><subject>Nicotinic Acids - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Skin - drug effects</subject><subject>Skin - pathology</subject><subject>Skin Diseases - chemically induced</subject><subject>Skin Diseases - pathology</subject><subject>Skin Diseases - prevention &amp; control</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Treatment Outcome</subject><issn>0011-9059</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqNkEtv3CAURlHUqpmk_QsRqpSlHV7GZtFFlDSPKm0WmSpLxABumHqMA1idya8vjkfNtitA95x7Lx8AEKMSI8bP1iWmvCoY5aQkCOESYUJZuT0Ai7nAKXkHFrmCC4EqcQiOYlznJyWYfQCHGPNaIMQXQJ3DwXU-wZhGs4PJQ2OTDRvXW5ieLLRta3WCvoVJvajgk82FX7aDeZNT6Pvs2eCdKVxvRm0NtIMz2VcdVCn44Wn3EbxvVRftp_15DH5efV1e3BR399e3F-d3ha4IY0VFG9JQpWqsEdda1VRXKyI0qRuqhWENIzgvj6tVnRkmBCIt0pogawQljaDH4PPcdwj-ebQxybUfQ59HSkJI_m2FUIaaGdLBxxhsK4fgNirsJEZyilau5ZSgnKKVU7TyNVq5zerJvv-42ljzJu6zzMDpHlBRq64NqtcuvnEM1Q1mJHNfZu6P6-zuvxeQt98up1v2i9l3OfvtP1-F35LXtK7k449r-bjklw_fOZVL-hfqWqEg</recordid><startdate>200107</startdate><enddate>200107</enddate><creator>Kaidbey, Kays</creator><creator>Kopper, Scott C.</creator><creator>Sefton, John</creator><creator>Gibson, John R.</creator><general>Blackwell Science Ltd</general><general>Blackwell Science</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>200107</creationdate><title>A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy</title><author>Kaidbey, Kays ; Kopper, Scott C. ; Sefton, John ; Gibson, John R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5244-538283aa71c06cca73c5b29c2783c9d4842121415b7a7149902f0cc20ed932893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adrenal Cortex Hormones - pharmacology</topic><topic>Adult</topic><topic>Atrophy - chemically induced</topic><topic>Atrophy - prevention &amp; control</topic><topic>Betamethasone - analogs &amp; derivatives</topic><topic>Betamethasone - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Dermatologic Agents - pharmacology</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Gels</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nicotinic Acids - pharmacology</topic><topic>Nicotinic Acids - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Skin - drug effects</topic><topic>Skin - pathology</topic><topic>Skin Diseases - chemically induced</topic><topic>Skin Diseases - pathology</topic><topic>Skin Diseases - prevention &amp; control</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaidbey, Kays</creatorcontrib><creatorcontrib>Kopper, Scott C.</creatorcontrib><creatorcontrib>Sefton, John</creatorcontrib><creatorcontrib>Gibson, John R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaidbey, Kays</au><au>Kopper, Scott C.</au><au>Sefton, John</au><au>Gibson, John R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2001-07</date><risdate>2001</risdate><volume>40</volume><issue>7</issue><spage>468</spage><epage>471</epage><pages>468-471</pages><issn>0011-9059</issn><eissn>1365-4632</eissn><coden>IJDEBB</coden><abstract>Background  Repeated applications of a corticosteroid can induce epidermal atrophy. This study was performed to investigate whether the adjunctive use of tazarotene gel 0.1% might help to minimize the development of steroid‐induced epidermal atrophy. Methods  Each of 24 healthy volunteers received the following six treatments (applied 6 days per week for 4 weeks), which were randomized to each of six sites on their forearms: no treatment, tazarotene vehicle, tazarotene vehicle + tazarotene gel 0.1%, diflorasone diacetate 0.05% ointment, diflorasone diacetate 0.05% ointment + tazarotene vehicle, or diflorasone diacetate 0.05% ointment + tazarotene gel 0.1%. Results  The mean epidermal thickness was increased by 20% (NS) and 62% (P ≤ 0.0005) after applications of tazarotene vehicle and tazarotene gel 0.1%, respectively. Application of diflorasone diacetate reduced the mean epidermal thickness by 43% (P ≤ 0.0005). Concomitant application of tazarotene gel 0.1% with diflorasone diacetate did not entirely prevent atrophy, but was shown to ameliorate 37% of the epidermal atrophy induced by diflorasone diacetate alone (P ≤ 0.003 compared with steroid monotherapy). Conclusions  Tazarotene gel 0.1% significantly reduces epidermal atrophy induced by diflorasone diacetate 0.05% ointment.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>11679006</pmid><doi>10.1046/j.1365-4362.2001.01234.x</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0011-9059
ispartof International journal of dermatology, 2001-07, Vol.40 (7), p.468-471
issn 0011-9059
1365-4632
language eng
recordid cdi_proquest_journals_222900500
source Wiley-Blackwell Read & Publish Collection
subjects Adrenal Cortex Hormones - pharmacology
Adult
Atrophy - chemically induced
Atrophy - prevention & control
Betamethasone - analogs & derivatives
Betamethasone - pharmacology
Biological and medical sciences
Biopsy
Dermatologic Agents - pharmacology
Dermatologic Agents - therapeutic use
Double-Blind Method
Female
Gels
Humans
Male
Medical sciences
Middle Aged
Nicotinic Acids - pharmacology
Nicotinic Acids - therapeutic use
Pharmacology. Drug treatments
Pilot Projects
Skin - drug effects
Skin - pathology
Skin Diseases - chemically induced
Skin Diseases - pathology
Skin Diseases - prevention & control
Skin, nail, hair, dermoskeleton
Treatment Outcome
title A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T21%3A24%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pilot%20study%20to%20determine%20the%20effect%20of%20tazarotene%20gel%200.1%25%20on%20steroid-induced%20epidermal%20atrophy&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Kaidbey,%20Kays&rft.date=2001-07&rft.volume=40&rft.issue=7&rft.spage=468&rft.epage=471&rft.pages=468-471&rft.issn=0011-9059&rft.eissn=1365-4632&rft.coden=IJDEBB&rft_id=info:doi/10.1046/j.1365-4362.2001.01234.x&rft_dat=%3Cproquest_cross%3E86943220%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5244-538283aa71c06cca73c5b29c2783c9d4842121415b7a7149902f0cc20ed932893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222900500&rft_id=info:pmid/11679006&rfr_iscdi=true